Akron is an innovative biotechnology company focused on providing raw materials and biological reagents, components for research and product development. The firm specialize in stem cell products, cell culture products, and cGMP raw materials providing innovative and compliant solutions to the cell and regenerative medicine arena. In September 2019 the firm was acquired by Arcline Investment Management. Not itself in related business endeavor, Arcline is described as a well endowed private equity firm that only invests in niche, market-leading companies that management feel passionate about owning. It is assumed that, SBIR eligiblity being primarily a function of size, Akron could in fact remain program eligible
